Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-14

Study Completion Date

2023-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase 1, first in human (FIH), single-centre, double-blind, randomized, placebo-controlled, dose escalating trial to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of CBS001 in healthy subjects. The study will be conducted in 2 parts:

Part A: Single ascending intravenous (IV) doses of CBS001 Part B: Multiple ascending IV doses of CBS001

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis

NCT01363388

Vasculitis

COMPLETED PHASE2

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

NCT05162066

Complement 3 Glomerulopathy Immunoglobulin A Nephropathy Membranous Nephropathy

TERMINATED PHASE2

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

NCT02222155

ANCA-associated Vasculitis

COMPLETED PHASE2

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT00685373

Cryopyrin-Associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Muckle Wells Syndrome +1 more

COMPLETED PHASE3

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

NCT03906227

ANCA Associated Vasculitis

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Inflammatory Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A - Cohort 1A

Single dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part A - Cohort 2A

Single dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part A - Cohort 3A

Single dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part A - Cohort 4A

Single dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part A - Cohort 5A

Single dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part A - Cohort 6A

Single dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part A - Cohort 7A

Single dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part A - Cohort 8A

Single dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part B - Cohort 1B

Multiple dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part B - Cohort 2B

Multiple dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Part A - Cohort 3B

Multiple dose cohort

Group Type EXPERIMENTAL

CBS001

Intervention Type DRUG

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Placebo

Intervention Type DRUG

CBS001 matched placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CBS001

Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.

Intervention Type DRUG

Placebo

CBS001 matched placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female healthy volunteer.
2. Aged 18-65 years.
3. A body mass index (BMI; Quetelet index) in the range 18.0-30.9. Body Mass Index = weight (kg)/(height\[m\]\^2
4. Ability to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
5. Willingness to give written consent to participate after reading the information and consent form (ICF), and after having the opportunity to discuss the trial with the investigator or their delegate.
6. Agree to follow the contraception requirements of the trial
7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication or until the final follow-up visit (whichever is longer).
8. Registered with a General Practitioner (GP) in the United Kingdom.
9. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).

Exclusion Criteria

1. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of contraception.
2. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
3. Isolated bilirubin \> 1.5 x upper limit of normal (ULN). Isolated bilirubin \> 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \< 35% indicative of Gilbert's syndrome.
4. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
5. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, allergic diseases such as asthma or atopic dermatitis requiring medication, or history of any psychotic mental illness.
6. Presence or history of severe adverse reaction to any drug or a history of sensitivity to any CBS001 excipient.
7. Use of a prescription medicine (except hormone contraceptives or hormone replacement therapy \[HRT\] in women) during the 28 days before the (first) dose of trial medication, or use of an over-the-counter medicine (except acetaminophen \[paracetamol\], dietary supplement, or herbal remedy) including St John's Wort during the 7 days before the (first) dose of trial medication.
8. Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before \[first\] admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
9. Receipt of an approved or investigational biological product within the 12 months before screening.
10. Receipt of a vaccination (except COVID-19 vaccine) within 28 days before (first) dose of trial medication, or planned vaccination during the study.
11. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly, or more than 10 cigarettes or 6.25 g of tobacco daily.
12. Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40-100 beats/min. Repeat measurements are permitted if values are borderline (ie values that are within 5 mm Hg for blood pressure or 5 beats/min for heart rate) or if requested
13. Corrected QT interval (QTcF) value greater than 450 msec (men) or greater than 470 msec (women) measured on 12-lead ECG at the screening examination. Triplicate measurements will be made, and a mean value used to determine eligibility. A repeat (in triplicate) is also allowed on 1 occasion for determination of eligibility. Participants can be included if the repeat value is within range or still borderline, but deemed not clinically significant by the investigator.
14. Possibility that the volunteer will not cooperate with the requirements of the protocol.
15. Evidence of drug abuse on urine testing.
16. Positive test for hepatitis B, hepatitis C (unless has received curative antiviral treatment and has a negative polymerase chain reaction \[PCR\] for viral load) or HIV. Loss of more than 400 mL blood during the 3 months before the study, eg as a blood donor.
17. Objection by GP to volunteer entering study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes